Information Provided By: 
Fly News Breaks for September 6, 2017
PBYI, ALNY, AVXS, BMRN, ONCE
Sep 6, 2017 | 17:34 EDT
Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.
News For ONCE;BMRN;AVXS;ALNY;PBYI From the Last 2 Days
There are no results for your query ONCE;BMRN;AVXS;ALNY;PBYI
